Summary
Europe Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)
The intravenous immunoglobulin market in Europe is expected to grow from US$ 3,495.39 million in 2022 to US$ 5,363.10 million by 2028. It is estimated to grow at a CAGR of 7.4% from 2022 to 2028.
Rising Prevalence of Immunodeficiency Diseases
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders.IVIG is a standard therapy to treat most primary immunodeficiencies (PID).
Rare genetic diseases can be chronic, weakening, and expensive to treat.Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets—a situation referred to as thrombocytopenia.
As per the Rare Diseases Organization, ~200,000 ITP cases are recorded across the region annually. Thus, the increasing prevalence of immunodeficiency diseases drives the intravenous immunoglobulin market.
Market Overview
Europe is the second largest market, owing to factors such as rise in the geriatric population, increase in the prevalence of immunodeficiencies and autoimmune diseases, and high demand for the development of new therapies in the region.In addition, growing funding for research & development activities is likely to add more opportunities in the region in the coming years.
The pharmaceutical industry in Germany holds the fourth largest position with small and mid-sized companies. According to the International Trade Administration (ITA), in 2019, the pharmaceutical market in Germany accounted for US$ 62.5 billion. The country is likely to remain one of the most attractive destinations for the global pharmaceutical industry in the coming years in terms of manufacturing and supply. The industry’s growth is driven by increasing investment in research and development and growing patent applications.
Local market players developing IVIg therapies are likely to favor market growth. For instance, Germany-based Biotest AG is developing polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases.
Europe Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
Europe Intravenous Immunoglobulin Market Segmentation
The Europe intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country.Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD.
The IgG segment registered the largest market share in 2022.
Based on application, the Europe intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
Based on distribution channel, the Europe intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
Based on end user, the Europe intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
Based on country, the market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
